Figure 1



The anticancer effect of KU113 to the NCI-N87 xenograft in the Balb/c nude mice
Vehicle
KU113, 15mg/kg,po,qd
KU113, 30mg/kg,po,qd
Lapatinib,80 mg/kg, po,bid
Tumor volume(mm3) Mean±SEM
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
Days after treatment

Figure 2



The anticancer effect of erlotinib, afatinib and KU113 on the H1975 xenograft in the nude mice
Tumor volume(mm3) Mean±SEM
Days after treatment
Vehicle
Erlotinib,100mg/kg,po,qd
afatinib,20mg/kg,po,qd
KU113,10mg/kg,po,qd
KU113,20mg/kg,po,qd
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30

Figure 3




KU-113
IV 1 mg/kg
PO 5 mg/kg
brain PO 5 mg/kg
1000
100
10
1
Conc (ng/mL)
0
4
8
12
16
20
24
Time (hr)

Figure 4


Afatinib (KU041)
IV 1 mg/kg
PO 5 mg/kg
Conc (ng/mL)
100
10
1
0
4
8
12
16
20
24
Time (hr)